Non-melanoma skin cancer (NMSC) is the most common post-transplant malignancy in solid organ transplant (SOT) recipients and occurs at a 7–53x higher incidence vs. the general population. Additiona...
Regeneron Pharmaceuticals unveiled promising results from the Phase I/II LINKER-MM1 trial of linvoseltamab in patients grappling with relapsed/refractory (R/R) multiple myeloma (MM) during the oral plenary session at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego. Linvoselta...
Find MoreCancer vaccines represent a novel approach in cancer treatment, leveraging the body's immune system to identify and eradicate cancer cells. Unlike traditional vaccines that prevent infectious diseases, cancer vaccines aim to stimulate an immune response against specific proteins found on cancer cells, potentially p...
Find MoreNectin-4, despite being a well-established oncology target, is currently underutilized in drug development compared to HER2, TROP2, and Claudin18.2. However, its significant potential is underscored by its prevalent overexpression in various cancer types, such as pancreatic, ovarian, cervical, head-and-neck, breast...
Find MoreKRAS mutations represent the most commonly encountered driver oncogene, implicated in approximately 25% of all human cancers, with KRASG12D emerging as a predominant isoform, particularly prevalent in pancreatic, colorectal, and non-small cell lung cancers. Despite its frequency, targeting KRASG12D poses distinct c...
Find MoreC2Dx Launched Next Generation Shaw Scalpel System On March 26, 2024, C2Dx, a privately-owned medical device company, announced the launch of its Next Generation Shaw Scalpel System. The Shaw Scalpel System has obtained 510(k) clearance from the FDA for the upgraded controller of its advanced surgical techn...
Find MoreVoydeya Receives FDA Approval as Supplemental Treatment with Ravulizumab or Eculizumab for Managing Extravascular Hemolysis in Adult Patients with PNH Voydeya (danicopan) has received approval in the United States for use alongside ravulizumab or eculizumab in treating extravascular hemolysis (EVH) in adults dia...
Find MoreNon-muscle-invasive bladder cancer represents a category of bladder cancer where the tumor is confined to the innermost layer of the bladder lining without invading the muscle. This early-stage form accounts for a significant proportion of bladder cancer cases. Among the 7MM, the US accounted for the highest num...
Find MoreIn the realm of cancer treatment, the development of targeted therapies has been nothing short of revolutionary. Among these advancements, EGFR inhibitors have emerged as a powerful weapon in the fight against certain types of cancer. EGFR, or Epidermal Growth Factor Receptor, is a protein found on the surface of c...
Find MoreRegeneron Updates Progress on Biologics License Application for Odronextamab Regeneron Pharmaceuticals, Inc. has announced that the FDA has issued Complete Response Letters (CRLs) regarding the Biologics License Application (BLA) for odronextamab in cases of relapsed/refractory (R/R) follicular lymphoma (FL) and...
Find MoreProstate Cancer is the second most common malignancy in men worldwide, after lung cancer. Most Prost.....
Find MoreMedical Marijuana is the medical use of Cannabis sativa or Cannabis indica plant to relieve symptoms.....
Find MoreIPSCs have enormous applications in the field of regenerative medicine, disease modelling, and drug .....
Find MoreHIV-associated lipodystrophy (HAL), is a condition characterized by the redistribution of adipose ti.....
Find MoreRetinitis pigmentosa is a gradual deterioration of the ability of eyes to see. The defect in the eye.....
Find MoreAcute ischemic stroke (AIS) is a medical emergency caused by decreased blood flow to the brain, whic.....
Find MoreThe American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.